CTLA4 and Miyoshi myopathy: In the past decade, the emergence of immune checkpoint inhibitors (ICIs) represented by antiprogrammed cell death-1 (PD-1) antibody and anticytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody brought enormous advances to the clinical management of CM but less so for MM.